Previous close | 8.36 |
Open | 8.94 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 8.72 - 8.94 |
52-week range | 2.80 - 16.16 |
Volume | |
Avg. volume | 3,256 |
Market cap | 608,536 |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LYON, France, March 21, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that it has obtained two financing operations, with the issuance of ordinary shares to the benefit of members of its management team, including the founding Soula family, and Vester Finance under the form of a capital increase wi
LYON, France, March 15, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat
LYON, France, March 06, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that its management team are scheduled to participate in the following upcoming conferences: